识别含有的胺作为强大的微管向性抗瘤剂
Bin Jiang1, Yijia Zheng2, Tiezheng Xue1
1Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China; Department of Pharmaceutical Chemistry, School of Pharmacy, Hebei Medical University, Shijiazhuang 050017, China.
Bioorganic chemistry
|March 16, 2025
概括
一种含有的新型化合物,2g通过向蛋白和克服耐药性,有效地抑制癌细胞的增殖. 需要进一步的研究来优化其前药物形式,以提高体内疗效.
科学领域:
- 药用化学 医学化学
- 癌症生物学 癌症生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 微管抑制剂在癌症治疗中至关重要.
- 药物耐药性,特别是P-gp过度表达,限制了治疗的有效性.
- 开发克服耐药性的新药是一种重大挑战.
研究的目的:
- 设计和合成新型含化合物作为潜在的抗癌剂.
- 评估化合物2g的抗增殖活性和作用机制.
- 评估化合物2g在克服多药耐药性的有效性及其作为前药物的潜力.
主要方法:
- 合成含有的酸和酸.
- 针对癌细胞系的体外抗增殖试验,包括P-gp过度表达的细胞系.
- 机理学研究涉及结合素,细胞循环分析和反应性氧物种 (ROS) 生成.
- 在体内使用MCF-7异种移植小鼠模型进行疗效评估.
- 开发和评估一种用于改善药理动学的前药物 (2g-P).
主要成果:
- 化合物2g表现出强烈的抗增殖活性,并结合到结核素的菌素部位.
- 2g诱导的G2/M细胞周期停止和产生的ROS.
- 2g对P-gp过度表达的细胞系表现出显著的疗效,与素和帕克利塔塞尔相比,药物耐药性指数较低.
- 在体内,2g在MCF-7异种移植模型中显示出大量的瘤生长抑制.
- 前药2g-P显示了改善的生物可用性,但在体内有效性降低,需要进一步调查.
结论:
- 化合物2g是一种有前途的新型含微管向剂,具有强大的抗癌活性和克服P-gp介导药物耐药性的能力.
- 这些发现为下一代微管抑制剂的设计提供了宝贵的见解.
- 需要进一步的研究来优化2g的前药物策略,以提高其治疗潜力.
相关概念视频
01:10Drugs that Destabilize Microtubules
1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K
01:15Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
01:45Destabilization of Microtubules
2.5K
The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
2.5K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
171
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
171
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K